**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 34055**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

**Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease**

Senhaji N *et al*. oxidative pathway related genes and IBD

Nezha Senhaji, Sellama Nadifi, Younes Zaid, Aurora Serrano, Daniel Arturo Leon Rodriguez, Nadia Serbati, Mehdi Karkouri, Wafaa Badre, Javier Martín

**Nezha Senhaji, Sellama Nadifi, Nadia Serbati,** Laboratory of Genetic and Molecular Pathology, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca 20100, Morocco

**Younes Zaid,** Mohammed VI University of Health Sciences, Casablanca 20000, Morocco

**Aurora Serrano, Daniel Arturo Leon Rodriguez, Javier Martin,** Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, P.T.S. Granada 18016, Spain

**Mehdi Karkouri,** Department of Pathology, CHU Ibn Rochd, Casablanca 20000, Morocco

**Wafaa Badre,** Department of Gastroenterology, CHU Ibn Rochd, Casablanca 20000, Morocco

**Author contributions:** Senhaji N carried out the molecular genetics studies, participated in the recruitment of patients and drafted the manuscript; Nadifi S conceived the study and participated in its design and coordination; Zaid Y has been involved in revising the manuscript. Serrano A participated in the molecular genetics study; Rodriguez DAL helped in the statistical analysis; Serbati N participated in the recruitment of patients and clinical data collection; Karkouri M and Badre W coordinated patients’ recruitment and provided the clinical data; Martin J conceived the study and revised the manuscript; All authors read and approved the final manuscript.

**Institutional review board statement:** The ethics committee of the Faculty of Medicine and Pharmacy of Casablanca approved the study in accordance with the declaration of Helsinki for experiments involving humans.

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest.

**Data sharing statement:** The datasets supporting the conclusions of this article are included within the article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Nezha senhaji, PhD,** Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II.

19, rue Tarik Ibnou Ziad, Faculté de Médecine et de Pharmacie, Casablanca 20100, Morocco. nezha.senhaji05@etude.univcasa.ma

**Telephone:** +212-6-65896590

**Received:** March 25, 2017

**Peer-review started:** March 29, 2017

**First decision:** April 21, 2017

**Revised:** May 14, 2017

**Accepted:** June 1, 2017

**Article in press:**

**Published online:**

**Abstract**

***Aim***

to investigate whether common variants in the oxidative pathway genes influence inflammatory bowel disease (IBD) risk among Moroccan patients.

***Methods***

The distribution of (TAAA)n\_rs12720460 and (CCTTT)n\_rs3833912 *NOS2A* microsatellite repeats, *HIF-1A*\_rs11549467 and *NFKB1*–94ins/delATTG\_rs28362491 was analyzed in 507 subjects grouped in 199 IBD and 308 healthy controls. Genotyping was performed with polymerase chain reaction-fluorescent method and the TaqMan® allelic discrimination technology.

***Results***

The allele and genotype frequencies of *HIF1A*\_rs11549467, *NFKB1*\_rs28362491 and *NOS2A*\_ (TAAA)n did not differ significantly between patients and controls. Analysis of *NOS2A*\_ (CCTTT)n markers evidenced differences between patients and healthy controls. A preferential presence of the (CCTTT)8 (*P =* 0.02; OR = 1.71, 95%CI: 1.07–2.74), (CCTTT)14 (*P =* 0.02; OR = 1.71, 95%CI: 1.06–2.76) alleles in IBD, (CCTTT)8 (*P =* 0.008; OR = 1.95, 95%CI: 1.17–3.23) in CD and (CCTTT)7 (*P =* 0.009; OR = 7.61, 95%CI: 1.25-46.08), (CCTTT)11 (*P =* 0.05; OR = 0.51, 95%CI: 0.25-1.01), (CCTTT)14 (*P =* 0.02; OR = 2.05, 95%CI: 1.07-3.94), (CCTTT)15 (*P =* 0.01; OR = 2.25, 95%CI: 1.16-4.35) repeats in UC patients indicated its possible association with higher disease risk which need to be confirmed in a larger sample size.

***Conclusion***

Our results suggest that the *NOS2A*\_ (CCTTT)n gene variations may influence IBD susceptibility in the Moroccan population.

**Key words:** *HIF1A*; *NFKB1*; *NOS2A*; Inflammatory bowel disease; Moroccan patients

**© The Author (s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This is the first study to assess the involvement of oxidative pathway related genes in inflammatory bowel disease (IBD) development and to determine a possible effect of these variants on clinical course. We genotyped 507 subjects grouped in 308 healthy controlsand 199 IBD patients for the (TAAA)n\_rs12720460 and (CCTTT)n\_rs3833912 *NOS2A* microsatellite repeats, *HIF-1A*\_rs11549467 and *NFKB1*–94ins/delATTG\_rs28362491 polymorphisms. The present study showed that *NOS2A*\_ (CCTTT)n gene variations may influence IBD susceptibility in the Moroccan population. However, our data do not support a role for the *NFKB1* and *HIF1A* polymorphisms in the pathogenesis of IBD.

Senhaji N, Nadifi S, Zaid Y, Serrano A, Rodriguez DAL, Serbati N, Karkouri M, Badre W, Martin J. Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease. *World J Gastroenterol* 2017; In press

**Introduction**

Inflammatory bowel disease (IBD), a chronic and relapsing-remitting disorder of the gastrointestinal tract, encompasses Crohn’s disease (CD) and ulcerative colitis (UC).

IBD was previously found mainly in Western countries, with higher prevalence reported in developed countries[1]. However, during the last few decades, incidence rates of the two major forms of IBD have been increasing in developing countries[2], including Morocco.

Chronic intestinal inflammation is a hallmark of both disorders, and is believed to result from a number of abnormal conditions. The involvement of oxidative damage in IBD development has been thoroughly documented. Oxidative stress mainly contributes to aberrant inflammatory responses of intestinal cells to commensal bacteria and dietary antigens. During IBD, activated leukocytes generate a wide spectrum of proinflammatory cytokines, in addition to excessive oxidative reactions that alter the redox equilibrium within the gut mucosa. Therefore, the capacity to maintain inflammation by induction of transcription factors and redox-sensitive signaling pathways may influence the occurrence and severity of the disease[3]. Induction of inducible nitric oxide synthase (iNOS) was reported to play a key role in oxidative stress-induced inflammation[4]. The genetic polymorphisms of the *NOS2A* (nitric oxide synthase) gene have been proposed to be involved in IBD aetiology[5]. Two functionally relevant polymorphisms located at *NOS2A* gene promoter region were reported, the first one is a highly polymorphic pentanucleotide (CCTTT)n microsatellite repeat which is important in the regulation of NOS2A transcription[6]. The second one is located at the proximal promoter region and consists of an insertion/deletion of one TAAA repeat[7].

Perpetuation of inflammation is also mediated by cellular stress responses of inflammatory cells that produce soluble mediators and reactive species which act by further inducing changes in transcription factors, among which hypoxia-inducible factor-1α (HIF-1α) and nuclear factor κB (NF-κB)[8]. HIF-1-α is a key regulator of cellular response to hypoxia, the gene encoding the HIF-1α subunit (HIF1A) carries a common missense mutation, A588T (G>A, rs11549467), that has been related to increased trans-activation capacity[9]. The involvement of HIF-1-α in the enhancement of the inflammatory response was demonstrated; elevated levels of HIF-1-α in biopsies of primary lesions of patients confirmed its role in inflammatory diseases[10]. HIF-1-α has been shown to induce the secretion of inflammatory mediators by indirect signaling through NF-kB-mediated cytokine and chemokine secretion[11].

NF-κB is activated during inflammation, giving rise to induction of gene expression of several genes involved in mucosal inflammation such as cytokines (TNFA, IL6, IL1β...), Cox-2, and NOS2A[12,13]. A functional *NFKB1* promoter polymorphism consisting of a common (-94ins/delATTG) insertion/deletion, that seems to affect promoter activity of the *NFKB1* gene and differential nuclear protein binding[14], was associated with the risk of CD and UC[14,15].

In search of relevant gene polymorphisms related to oxidative stress signaling that are involved in IBD development, we explored the association of *HIF1A*\_rs11549467, *NFKB1*\_rs28362491 *NOS2A* (CCTTT)n\_rs3833912 and *NOS2A* (TAAA)\_rs12720460 polymorphisms with IBD (CD and UC) in a Moroccan population.

**Materials and methods**

***Study population***

Peripheral blood was obtained from 308 healthy unrelated blood donors. 199 patients diagnosed with IBD at the CHU Ibn Rochd Hospital (Casablanca, Morocco) were included in this study. The diagnosis of CD or UC was established according to conventional endoscopic, clinical, histological and radiological criteria as previously described[16,17]. CD phenotype was classified according to the Montreal classification[18]. UC anatomic location was subgrouped using Paris classification[19]. Patient’s clinical and demographic characteristics were collected in a case report form including questions on disease location and phenotype, age at diagnosis and other clinical features.

***Ethics statement***

The ethics committee of the Faculty of Medicine and Pharmacy of Casablanca approved the study in accordance with the declaration of Helsinki for experiments involving humans, and a written informed consent was obtained from all participants.

***DNA analysis***

Genomic DNA was extracted from peripheral blood using the salting out procedure and from Formalin Fixed Paraffin Embedded Tissues using the QIAamp® DNA FFPE Tissue Kit (Qiagen). DNA quality and quantity was determined with the NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE) and the QuBit Quantification Platform (Invitrogen, Ltd., Paisley, United Kingdom) using the QuBit high-sensitivity assay reagents.

The *NOS2A* (TAAA)n\_rs12720460 and (CCTTT)n\_rs3833912 genotyping was performed using a polymerase chain reaction (PCR)-based method combined with fluorescent technology as previously described[20]. Forward and reverse primers were.

F: 5’-TGC CAC TCC GCT CCA G-3’; R: 5’-GGC CTC TGA GAT GTT GGT CTT-3’for (TAAA)n, and F: 5’-ACC CCT GGA AGC CTA CAA CTG CAT-3’; R: 5’-GCC ACT GCACCC TAG CCT GTC TCA-3’ for (CCTTT)n. The forward primers were 5’ labeled with the fluorescent dye 6-Carboxyfluorescein amino hexy FAM. The different alleles were resolved after capillary electrophoresis on automated DNA sequencer (ABI 3130xl Genetic Analyzer, Applied Biosystems) and analyzed with the GeneMapper® 4.0 software (Applied Biosystems). Selected samples from each genotype were sequenced in order to confirm the length of each allele.

Genotyping of *HIF1A* (G/A) rs11549467 and *NFKB1*–94ins/delATTG (rs28362491) was performed on the Light Cycler 480 System (Roche, Barcelona, Spain) using a pre-designed TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, United States) as previously described[21,22]. PCR was carried out in a total reaction volume of 5 μl with the following amplification protocol: initial denaturation at 95°C for 3 min followed by 50 cycles of denaturation at 95 °C for 3 s, and annealing/extension at 60 °C for 20 s. The primer sequences of *NFKB1* promoter polymorphism IN/DEL -94ATTG were: F: 5’-GCC TCC GTG CTG CCT-3’ and R: 5’-AGG GAA GCC CCC AGGAA-3’, and the probe sequences were NFKB1-INS: 5’-VIC-CCCGACCATTGATTGG-NFQ-3’ and NFKB1-DEL: 5’-FAM-TTCCCCGACCATTGG-NFQ-3’.

***Statistical analysis***

Genotype and allele distributions among patients with CD, UC and IBD versus healthy controls were compared using the *χ2* test or Fisher test as appropriate. Odds ratios (ORs) with a confidence interval (CI) of 95% were assessed to measure the strength of association. Statistical power was calculated using Power Calculator of Genetic Studies 2006 software (<http://www.sph.umich.edu/csg/abecasis/CaTS/>). A chi-square test was used to test for deviation from Hardy-Weinberg equilibrium (HWE). Statistical analyses were performed with Plink software V1.07 (<http://pngu.mgh.harvard.edu/purcell/plink/>). *P*-value<0.05 was considered to be statistically significant. Bonferroni correction was applied to significant *P*-values of *NOS2A* polymorphisms to correct by the number of comparisons.

**Results**

One hundred ninety-nine patients with IBD (136 CD; 63 UC) and 308 control subjects were included in this study. The success rates of genotyping assays ranged between 95% and 100%. Baseline demographic and clinical characteristics of cases were reported in a previous paper[23] and are presented in Table 1. Differences in our cohort between CD and UC patients in terms of age at diagnosis and gender distribution are to be underlined.

***HIF1A (G/A) rs11549467 and NFKB1 –94ins/del ATTG (rs28362491) polymorphisms***

In both patients and controls, the genotype distribution of examined polymorphisms complied with the Hardy-Weinberg expectations.

In order to study associations of *HIF1A* (rs11549467) and *NFKB1* (rs28362491) variants in IBD overall and in CD and UC in particular, the distribution of polymorphic alleles was assessed. Genotype and allele frequencies are given in Tables 2 and 3.

The analysis of both *HIF1A* (rs11549467) and *NFKB1* (rs28362491) polymorphisms distribution among patients and controls did not reveal any statistically significant association, both in terms of allele and genotype frequencies. Similarly, we did not observe any effect on disease risk when Genetic models were assessed (Table 3).

***NOS2A (TAAA)n and (CCTTT)n repeat microsatellite repeat polymorphisms***

We explored the potential influence of *NOS2A* polymorphisms on the susceptibility to IBD in the Moroccan population. Tables 4 and 5 show the distribution of the pentanucleotide (CCTTT)n microsatellite alleles in controls, IBD, CD and UC cases. Ten different alleles, comprising of 7-16 repeats i.e. 171-216 bp, were observed in our population. (CCTTT)12 was observed to be the most frequent allele in IBD (21.2%), CD (21.7%), UC cases (20.0%) and controls (22.0%). The overall (CCTTT)n distribution showed differences between cases and controls. The average amount of CCTTT tandem repeats was shown to be less in CD and more in UC patients compared to controls.

When individual CCTTT alleles were analyzed, a significant increase in frequency of the 8-repeat (10.2% *vs* 6.2%; *P =* 0.02, OR = 1.71, 95%CI: 1.07–2.74) and 14-repeat (9.9% *vs* 6.2%; *P =* 0.02, OR = 1.71, 95%CI: 1.06–2.76) alleles was observed in IBD cases compared with controls respectively.

Similarly the (CCTTT)8 repeat/allele was found to be higher in CD patients cohort as compared to controls (11.4% *vs* 6.2%; *P =* 0.008, OR = 1.95, 95%CI: 1.17–3.23). Whereas the increased distribution of the (CCTTT)14 repeat among CD cases compared to controls did not reach the significance level (9.1% *vs* 6.2%; *P =* 0.09, OR = 1.56, 95%CI: 0.91–2.68).

Furthermore, determination of allele frequencies in UC patients revealed significant association of the 7, 11, 14 and 15 repeats polymorphic forms of the microsatellite to disease risk. Similar trend, though non-significant, was observed for the 16 repeat (*P =* 0.06, OR = 3.79, 95%CI: 0.83–17.18).

However, it should be noted that after Bonferroni correction by the number of comparisons, none of the observed associations remained significant in all patient groups.

We further analyzed the distribution of TAAA insertion/deletion polymorphism of *NOS2A* gene in our population. In this regard, no statistically significant allele or genotype differences were observed between IBD patients and controls (Table 6). Nor were significant differences between stratified CD and UC patients when compared to controls.

**Discussion**

IBD is an inflammatory disease resulting from a compound effect of a number of abnormal conditions. Genetic factors may play a pivotal role in the development of IBD. In this regard, we explored the potential contribution of genetic polymorphisms of oxidative pathway genes to the risk of IBD development. Our attention was focused on functionally relevant polymorphisms located in the *NOS2A* and *NFKB1* genes, and a common missense mutation of *HIF1A* gene.

We found differential distribution of (CCTTT)n microsatellite repeats between patients and controls; namely the (CCTTT)8 and (CCTTT)14 repeats for IBD, the (CCTTT)8 for CD and the (CCTTT)7, (CCTTT)11, (CCTTT)14 and (CCTTT)15 repeats for UC patients. As for Caucasians, the most common allele observed in our population was the 12 repeats instead of 10 and 11 repeats for Northwestern Colombians[20]. To our knowledge only two reports investigated the involvement of *NOS2A* gene polymorphisms in IBD etiology. Concordantly to our results, Martín *et al*[5] evidenced the influence of the inducible nitric oxide synthase (CCTTT)n microsatellite repeats on UC risk. However, in contrast to our finding, Oliver *et al*[24] demonstrated no tendency toward an association with IBD predisposition. This discrepant observation can be explained by geographic factors and ethnicity-related gene effect on disease susceptibility. Results from case-control studies may be influenced by population stratification, selection bias, phenotypic heterogeneity and low power to detect true associations. Thereby, it is likely that differences in the features related to the population investigated could be responsible in part for the controversy over the influence of *NOS2A*polymorphisms on IBD.

Polymorphisms of *NOS2A* have also been involved in other autoimmune diseases such multiple sclerosis and rheumatoid arthritis[25,26].In terms of functional relevance, CCTTT polymorphic markers have been described to affect nitric oxide synthase (NOS) transcription[6]. Another study has also reported that the number of CCTTT repeats was shown to influence transcription of *NOS2* gene in which the transcriptional activity was much greater in fibroblasts transfected by a vector with a long allele of the CCTTT repeat than in those transfected by a vector with a short allele[[36](#_ENREF_27)].

Considering the different contribution that short and long alleles seem to exert, tandem repeats variation within the promoter region of *NOS2* gene could explain the differences observed in our study between case and control subjects. Likewise, the cumulative effect of CCTTT repeats number, which is less in CD and more in UC compared to controls might yield a progressive increase in *NOS2* gene expression and excessive production of NO. Enhanced levels of NO can promote tissue injury and contribute to IBD activity and progression. Our results should however be interpreted with caution due to small sample size.

The involvement of the inducible (calcium-independent) isoform, iNOS in inflammation has been largely demonstrated[27] and is directly related to the large amounts of NO produced by the enzyme after transcriptional induction and the injurious levels of RNS generated by activated leukocytes, macrophages and epithelial cells in the intestinal mucosa[28]. The overexpression of iNOS during active IBD is characterized by elevated rectal NO levels[29]. Biopsies of UC-active patients demonstrate higher iNOS transcripts and enzyme levels as compared to controls or healthy relatives[30]. It was also demonstrated that in UC, greatly increased production of iNOS-derived NO reacts with tyrosine leading to production of nitrotyrosine which is associated with infiltration of neutrophils in the epithelium[31].

On the other hand, the present study sought to assess the association of *HIF1A* (G/A) rs11549467 and *NFKB1*–94ins/del ATTG (rs28362491) polymorphisms with IBD among Moroccan patients. Data on association of these genes with IBD in the North African population are currently lacking. Our results suggest that the studied *NFKB1* gene variation do not influence susceptibility to IBD (CD and UC) in the cohort tested herein. Our findings are in accordance with previous investigations analyzing Spanish[32] British[33] and German populations[34]. In contrast, an association of the –94ins/del ATTG polymorphism with UC was demonstrated in a North American population[14]. These discrepant results may have been caused by clinical, population and genetic differences in addition to ethnic origin heterogeneity.

Moreover, the present case-control study could not establish a role for *HIF1A* (G/A) rs11549467 polymorphism in the pathogenesis of both CD and UC and also found no evidence for disease risk when evaluating genetic models. This later polymorphism was shown to be associated with autoimmune diseases such as systemic sclerosis[35]; however no investigation has assessed its involvement in IBD etiology.

Our results suggest that, variation in the distribution of CCTTT repeats in the *NOS2A* gene may differentially contribute to CD and UC development in the Moroccan population. Additionally, contrary to what was initially expected, no significant differences were found between patients and healthy subjects in the frequency of the *NFKB1* and *HIF1A* polymorphisms. Thereby, our data do not support a role for these polymorphisms in the pathogenesis of IBD in the Moroccan population.

**Acknowledgements**

We gratefully acknowledge all the members of LGMP and the Gastroenterology department. We also thank Prof. Adam Ziad from Florida Atlantic University for copy-editing our manuscript.

**COMMENTS**

***Background***

Inflammatory bowel disease (IBD), a chronic and relapsing-remitting disorder of the gastrointestinal tract, encompasses Crohn’s disease (CD) and ulcerative colitis (UC). Chronic intestinal inflammation is a hallmark of both disorders, and is believed to result from a number of abnormal conditions. The involvement of oxidative damage in IBD development has been thoroughly documented. However, the genetic factors involved in this process have not been elucidated in the Moroccan population.

***Research frontiers***

Oxidative stress was reported to play a key role in the induction and perpetuation of inflammation. In search of relevant gene polymorphisms related to oxidative stress signaling that are involved in IBD development, we explored the association of *HIF1A*\_rs11549467, *NFKB1*\_rs28362491 *NOS2A* (CCTTT)n\_rs3833912 and *NOS2A* (TAAA)\_rs12720460 polymorphisms with IBD (CD and UC) in Moroccan patients.

***Innovations and breakthroughs***

This study found that variation in the distribution of CCTTT repeats in the *NOS2A* gene may contribute to IBD development in the Moroccan population. Additionally, no significant differences were found between patients and healthy subjects in the frequency of the *NFKB1* and *HIF1A* polymorphisms. Thereby, our data do not support a role for these polymorphisms in the pathogenesis of IBD in our study cohort.

***Applications***

By assessing and identifying the genetic polymorphisms associated with susceptibility to inflammatory bowel disease, this study could represent a future preliminary basis for personalized medicine and targeted therapy in disease management.

***Terminology***

Oxidative stress is identified as an imbalance between the prooxidants and antioxidants in the body. Oxidative stress produced due to unresolved and persistent inflammation can be a major factor involved in the change of the dynamics of immune responses.

The mechanism by which oxidative stress and redox signaling induces inflammation in IBD is demonstrated by an increase in the levels of reactive oxygen and nitrogen species (ROS/RNS) in both human subjects and experimental animals.

***Peer-review***

This is an interesting paper, concerning the role of genetic factors related to the oxidative pathway in the susceptibility of inflammatory bowel disease. There are some points that need to be addressed.

**References**

1 **Esmat S**, El Nady M, Elfekki M, Elsherif Y, Naga M. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. *World J Gastroenterol* 2014; **20**: 814-821 [PMID: 24574754 DOI: 10.3748/wjg.v20.i3.814]

2 **Cosnes J**, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1785-1794 [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055]

3 **Biasi F**, Leonarduzzi G, Oteiza PI, Poli G. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. *Antioxid Redox Signal* 2013; **19**: 1711-1747 [PMID: 23305298 DOI: 10.1089/ars.2012.4530]

4 **Zhu H**, Li YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. *Exp Biol Med (Maywood)* 2012; **237**: 474-480 [PMID: 22442342 DOI: 10.1258/ebm.2011.011358]

5 **Martín MC**, Martinez A, Mendoza JL, Taxonera C, Díaz-Rubio M, Fernández-Arquero M, de la Concha EG, Urcelay E. Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. *Immunogenetics* 2007; **59**: 833-837 [PMID: 17955236 DOI: 10.1007/s00251-007-0255-1]

6 **Warpeha KM**, Xu W, Liu L, Charles IG, Patterson CC, Ah-Fat F, Harding S, Hart PM, Chakravarthy U, Hughes AE. Genotyping and functional analysis of a polymorphic (CCTTT) (n) repeat of NOS2A in diabetic retinopathy. *FASEB J* 1999; **13**: 1825-1832 [PMID: 10506586]

7 **Bellamy R**, Hill AV. A bi-allelic tetranucleotide repeat in the promoter of the human inducible nitric oxide synthase gene. *Clin Genet* 1997; **52**: 192-193 [PMID: 9377812]

8 **Reuter S**, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? *Free Radic Biol Med* 2010; **49**: 1603-1616 [PMID: 20840865 DOI: 10.1016/j.freeradbiomed.2010.09.006]

9 **Tanimoto K**, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. *Carcinogenesis* 2003; **24**: 1779-1783 [PMID: 12919954 DOI: 10.1093/carcin/bgg132]

10 **Biddlestone J**, Bandarra D, Rocha S. The role of hypoxia in inflammatory disease (review). *Int J Mol Med* 2015; **35**: 859-869 [PMID: 25625467 DOI: 10.3892/ijmm.2015.2079]

11 **Scortegagna M**, Cataisson C, Martin RJ, Hicklin DJ, Schreiber RD, Yuspa SH, Arbeit JM. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. *Blood* 2008; **111**: 3343-3354 [PMID: 18199827 DOI: 10.1182/blood-2007-10-115758]

12 **Yasukawa K**, Tokuda H, Tun X, Utsumi H, Yamada K. The detrimental effect of nitric oxide on tissue is associated with inflammatory events in the vascular endothelium and neutrophils in mice with dextran sodium sulfate-induced colitis. *Free Radic Res* 2012; **46**: 1427-1436 [PMID: 22998024 DOI: 10.3109/10715762.2012.732698]

13 **Tak PP**, Firestein GS. NF-kappaB: a key role in inflammatory diseases. *J Clin Invest* 2001; **107**: 7-11 [PMID: 11134171 DOI: 10.1172/JCI11830]

14 **Karban AS**, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. *Hum Mol Genet* 2004; **13**: 35-45 [PMID: 14613970 DOI: 10.1093/hmg/ddh008]

15 **Bank S**, Skytt Andersen P, Burisch J, Pedersen N, Roug S, Galsgaard J, Ydegaard Turino S, Brodersen JB, Rashid S, Kaiser Rasmussen B, Avlund S, Bastholm Olesen T, Jürgen Hoffmann H, Kragh Thomsen M, Ostergaard Thomsen V, Frydenberg M, Andersen Nexø B, Sode J, Vogel U, Andersen V. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. *PLoS One* 2014; **9**: e98815 [PMID: 24971461 DOI: 10.1371/journal.pone.0098815]

16 **Senhaji N**, Diakité B, Serbati N, Zaid Y, Badre W, Nadifi S. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms: New data and a meta-analysis. *BMC Gastroenterol* 2014; **14**: 206 [PMID: 25492126 DOI: 10.1186/s12876-014-0206-x]

17 **Senhaji N**, Serbati N, Diakité B, Arazzakou S, Hamzi K, Badre W, Nadifi S. Methylenetetrahydrofolate reductase C677T variant in Moroccan patients with inflammatory bowel disease. *Gene* 2013; **521**: 45-49 [PMID: 23542077 DOI: 10.1016/j.gene.2013.02.046]

18 **Silverberg MS**, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; **19** Suppl A: 5A-36A [PMID: 16151544]

19 **Levine A**, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis* 2011; **17**: 1314-1321 [PMID: 21560194 DOI: 10.1002/ibd.21493]

20 **Gómez LM**, Anaya JM, Vilchez JR, Cadena J, Hinojosa R, Vélez L, Lopez-Nevot MA, Martín J. A polymorphism in the inducible nitric oxide synthase gene is associated with tuberculosis. *Tuberculosis (Edinb)* 2007; **87**: 288-294 [PMID: 17475563 DOI: 10.1016/j.tube.2007.03.002]

21 **Torres O**, Palomino-Morales R, Vazquez-Rodriguez TR, Gamallo C, Morado IC, Miranda-Filloy JA, Amigo-Diaz E, Callejas-Rubio JL, Fernadez-Gutierrez B, Castañeda S, Morado IC, Martin J, Gonzalez-Gay MA. Lack of association between hypoxia inducible factor-1 alpha gene polymorphisms and biopsy-proven giant cell arteritis. *Clin Exp Rheumatol* 2010; **28**: 40-45 [PMID: 20412701]

22 **López-Mejías R**, García-Bermúdez M, González-Juanatey C, Castañeda S, Miranda-Filloy JA, Gómez-Vaquero C, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, Blanco R, González-Álvaro I, Llorca J, Martín J, González-Gay MA. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. *Atherosclerosis* 2012; **224**: 426-429 [PMID: 22742859 DOI: 10.1016/j.atherosclerosis.2012.06.008]

23 **Senhaji N**, Serrano A, Badre W, Serbati N, Karkouri M, Zaid Y, Nadifi S, Martin J. Association of inflammatory cytokine gene polymorphisms with inflammatory bowel disease in a Moroccan cohort. *Genes Immun* 2016; **17**: 60-65 [PMID: 26632999 DOI: 10.1038/gene.2015.52]

24 **Oliver J**, Gómez-Garcia M, Vilchez JR, López-Nevot MA, Piñero A, Correro F, Nieto A, Martín J. Inducible and endothelial nitric oxide synthase genes polymorphism in inflammatory bowel disease. *Tissue Antigens* 2006; **67**: 326-330 [PMID: 16634870 DOI: 10.1111/j.1399-0039.2006.00578.x]

25 **Gonzalez-Gay MA**, Llorca J, Sanchez E, Lopez-Nevot MA, Amoli MM, Garcia-Porrua C, Ollier WE, Martin J. Inducible but not endothelial nitric oxide synthase polymorphism is associated with susceptibility to rheumatoid arthritis in northwest Spain. *Rheumatology (Oxford)* 2004; **43**: 1182-1185 [PMID: 15226517 DOI: 10.1093/rheumatology/keh283]

26 **Barcellos LF**, Begovich AB, Reynolds RL, Caillier SJ, Brassat D, Schmidt S, Grams SE, Walker K, Steiner LL, Cree BA, Stillman A, Lincoln RR, Pericak-Vance MA, Haines JL, Erlich HA, Hauser SL, Oksenberg JR. Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. *Ann Neurol* 2004; **55**: 793-800 [PMID: 15174013 DOI: 10.1002/ana.20092]

27 **Nathan C**. Inducible nitric oxide synthase: what difference does it make? *J Clin Invest* 1997; **100**: 2417-2423 [PMID: 9366554 DOI: 10.1172/JCI119782]

28 **Dijkstra G**, Moshage H, van Dullemen HM, de Jager-Krikken A, Tiebosch AT, Kleibeuker JH, Jansen PL, van Goor H. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. *J Pathol* 1998; **186**: 416-421 [PMID: 10209492 DOI: 10.1002/ (SICI)1096-9896 (199812)186: 4<416: : AID-PATH201>3.0.CO; 2-U]

29 **Ljung T**, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellstrom PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders. *World J Gastroenterol* 2006; **12**: 3386-3392 [PMID: 16733856]

30 **Herbst JJ**, Johnson DG, Oliveros MA. Gastroesophageal reflux with protein-losing enteropathy and finger clubbing. *Am J Dis Child* 1976; **130**: 1256-1258 [PMID: 984011]

31 **Singer II**, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, Stenson WF. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. *Gastroenterology* 1996; **111**: 871-885 [PMID: 8831582]

32 **Oliver J**, Gómez-García M, Paco L, López-Nevot MA, Piñero A, Correro F, Martín L, Brieva JA, Nieto A, Martín J. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. *Inflamm Bowel Dis* 2005; **11**: 576-579 [PMID: 15905705]

33 **Mirza MM**, Fisher SA, Onnie C, Lewis CM, Mathew CG, Sanderson J, Forbes A. No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. *Gut* 2005; **54**: 1205-1206 [PMID: 16009698 DOI: 10.1136/gut.2005.070029]

34 **Glas J**, Török HP, Tonenchi L, Müller-Myhsok B, Mussack T, Wetzke M, Klein W, Epplen JT, Griga T, Schiemann U, Lohse P, Seiderer J, Schnitzler F, Brand S, Ochsenkühn T, Folwaczny M, Folwaczny C. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. *Inflamm Bowel Dis* 2006; **12**: 606-611 [PMID: 16804398 DOI: 10.1097/01.ibd.0000225346.23765.6b]

35 **Wipff J**, Dieude P, Avouac J, Tiev K, Hachulla E, Granel B, Diot E, Sibilia J, Mouthon L, Meyer O, Kahan A, Boileau C, Allanore Y. Association of hypoxia-inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population. *Scand J Rheumatol* 2009; **38**: 291-294 [PMID: 19306159 DOI: 10.1080/03009740802629432]

36 **Kawaguchi Y**, Tochimoto A, Hara M, Kawamoto M, Sugiura T, Katsumata Y, Okada J, Kondo H, Okubo M, Kamatani N. NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity. *Arthritis Res Ther* 2006; **8**: R104 [PMID: 16813666 DOI: 10.1186/ar1984]

**P-Reviewer:** Decorti G, Martin-Villa JM **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Morocco

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Basic characteristics of inflammatory bowel disease patients**

|  |  |  |
| --- | --- | --- |
| Patient characteristics | CD (*n* = 136) | UC (*n* = 63) |
| Gender | Male | 96 | 34 |
| Female | 40 | 29 |
| Age at diagnosis | < 16 | 16 | 1 |
| 17-40 | 79 | 34 |
| ≥ 40 | 22 | 19 |
| Data not available | 19 | 9 |
| Location of CD (%) | L1±L4 | 38 (28) | - |
| L2±L4 | 30 (22) | - |
| L3±L4 | 53 (39) | - |
| L4 | 4 (3) | - |
| Data not available | 11 (8) | - |
| Behavior of CD (%) | B1±p | 35 (26) | - |
| B2±p | 47 (34) | - |
| B3±p | 39 (29) | - |
| Data not available | 15 (11) | - |
| Location of UC (%) | E1 | - | 5 (8) |
| E2 | - | 24 (38) |
| E3 | - | 8 (12) |
| E4 | - | 13 (21) |
| Data not available | - | 13 (21) |
| Smoking habits | Yes | 35 | 11 |
| No | 67 | 32 |
| Data not available | 34 | 20 |

CD: Crohn’s disease; UC: ulcerative colitis.

**Table 2** **Minor Allele Frequencies of *HIF1A* and *NFKB1* genetic variants in inflammatory bowel disease patients and healthy controls from Morocco**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP** | **Group** | **Number of alleles** | **MAF (%)** | **Allele test** |
| **OR (95%CI)** | ***P*-value** |
| *HIF1A* | rs11549467 | Controls (*n =* 308) | 74/542 | 12.01 |  |  |
|  |  |
| IBD (*n =* 199) | 50/348 | 12.56 | 1.05 (0.72-1.54) | 0.79 |
| CD (*n =* 136) | 36/236 | 13.24 | 1.12 (0.73-1.71] | 0.61 |
| UC (*n =* 63) | 14/112 | 11.11 | 0.92 (0.50-1.68) | 0.77 |
| *NFKB1* | rs28362491-94ATTG ins/del | Controls (*n =* 308) | 257/359 | 41.72 |  |
| IBD (*n =* 199) | 167/231 | 41.96 | 1.01 (0.78-1.30) | 0.93 |
| CD (*n =* 136) | 113/159 | 41.54 | 0.99 (0.74-1.33) | 0.96 |
| UC (*n =* 63) | 54/72 | 42.86 | 1.05 (0.71-1.54) | 0.81 |

IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis; MAF: minor allele frequencies.

**Table 3 Genotype and genetic models distribution of*HIF1A* and *NFKB1*SNPs in inflammatory bowel disease patients and controls *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***SNP ID*** | **1/2** | **Subgroup** | **Genotype** | **Genotype 11+12 *vs* 221** | **Genotype 11 *vs* 12+222** |
| **OR (95%CI)** | ***P*-value** | **OR (95%CI)** | ***P*-value** |
| ***HIF1A***rs11549467 | **A/G** |  | AA | GA | GG |  |  |
| **Controls** | 4 (1.30) | 66 (21.43) | 238 (77.27) |
| **IBD** | 2 (1.01) | 46 (23.12) | 151 (75.88) | 1.08 (0.71-1.64) | 0.71 | 0.77 (0.14-4.25) | 0.76 |
| **CD** | 2 (1.47) | 32 (23.53) | 102 (75.00) | 1.13 (0.70-1.81) | 0.60 | 1.13 (0.20-6.26) | 0.88 |
| **UC** | 0 (0.00) | 14 (22.22) | 49 (77.78) | 0.97 (0.50-1.86) | 0.93 | NA | 0.99 |
| ***NFKB1***rs28362491 | **Del/Ins** |  | del/del | ins/del | ins/ins |  |  |
| **Controls** | 58 (18.83) | 141 (45.78) | 109 (35.39) |
| **IBD** | 37 (18.59) | 93 (46.73) | 69 (34.67) | 1.03 (0.71-1.5) | 0.86 | 0.98 (0.62-1.55) | 0.94 |
| **CD** | 25 (18.38) | 63 (46.32) | 48 (35.29) | 1.00 (0.65-1.53) | 0.98 | 0.97 (0.57-1.63) | 0.91 |
| **UC** | 12 (19.05) | 30 (47.62) | 21 (33.33) | 1.09 (0.61-1.94) | 0.75 | 1.01 (0.50-2.02) | 0.96 |

1Dominant model; 2Recessive model. IBD: inflammatory bowel disease; CD: Crohn disease; UC: ulcerative colitis; NA : Not applicable.

**Table 4 Allelic frequencies of (CCTTT)n microsatellite polymorphism of *NOS2A* gene for Moroccan inflammatory bowel disease patients and healthy controls *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Repeat no. | Size (bp) | Controls2*n =*596 | IBD2*n =*382 | *P* value | OR (95%CI) |
| 7 | 171 | 2 (0.3) | 4 (1.04) | 0.16 | 3.14 (0.57-17.24) |
| 8 | 176 | 37 (6.2) | 39 (10.2) |  **0.021** | 1.71 (1.07-2.74) |
| 9 | 181 | 75 (12.5) | 54 (14.1) | 0.48 | 1.14 (0.78-1.66) |
| 10 | 186 | 89 (15.0) | 46 (12.04) | 0.20 | 0.77 (0.53-1.14) |
| 11 | 191 | 90 (15.1) | 45 (11.8) | 0.14 | 0.75 (0.51-1.10) |
| 12 | 196 | 131 (22.0) | 81 (21.2) | 0.77 | 0.95 (0.69-1.30) |
| 13 | 201 | 99 (16.6) | 50 (13.9) | 0.13 | 0.75 (0.52-1.09) |
| 14 | 206 | 36 (6.2) | 38 (9.9) |  **0.022** | 1.71 (1.06-2.76) |
| 15 | 211 | 33 (5.5) | 22 (5.8) | 0.88 | 1.04 (0.59-1.81) |
| 16 | 216 | 4 (0.6) | 3 (0.7) | 0.83 | 1.17 (0.26-5.26) |

1*P =* 0.02, OR(95%CI): 1.71 (1.07-2.74): Bonferroni’s corrected *P*c = 0.2; 2*P =* 0.02, OR (95%CI): 1.71 (1.06–2.76): *P*c = 0.2. IBD: inflammatory bowel disease.

**Table 5 Allelic frequencies of (CCTTT)n microsatellite polymorphism of *NOS2A* gene for Crohn disease, ulcerative colitis patients and healthy controls *n* (%)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Repeat no. | Size (bp) | Controls2*n =*596  | CD2*n =*262  | *P* value | OR(95%CI) | UC2*n =*120 (%) | *P* value | OR(95%CI) |
| 7 | 171 | 2 (0.3) | 1 (0.4) | 0.91 | 1.13 (0.10-12.6) | 3 (2.5) | **0.009b** | 7.61 (1.25-46.08) |
| 8 | 176 | 37 (6.2) | 30 (11.4) | **0.008a** | 1.95 (1.17-3.23) | 9 (7.5) | 0.59 | 1.22 (0.57-2.61) |
| 9 | 181 | 75 (12.5) | 43 (16.4) | 0.13 | 1.36 (0.90-2.04) | 11 (9.1) | 0.29 | 0.70 (0.36-1.36) |
| 10 | 186 | 89 (15.0) | 33 (12.6) | 0.36 | 0.82 (0.53-1.26) | 13 (10.8) | 0.24 | 0.69 (0.37-1.28) |
| 11 | 191 | 90 (15.1) | 35 (13.3) | 0.50 | 0.86 (0.56-1.32) | 10 (8.3) | **0.05c** | 0.51 (0.25-1.01) |
| 12 | 196 | 131 (22.0) | 57 (21.7) | 0.94 | 0.98 (0.69-1.40) | 24 (20.0) | 0.63 | 0.88 (0.54-1.44) |
| 13 | 201 | 99 (16.6) | 31 (11.8) | 0.07 | 0.67 (0.43-1.03) | 19 (15.8) | 0.83 | 0.94 (0.55-1.61) |
| 14 | 206 | 36 (6.2) | 24 (9.1) | 0.09 | 1.56 (0.91-2.68) | 14 (11.6) | **0.02d** | 2.05 (1.07-3.94) |
| 15 | 211 | 33 (5.5) | 8 (3.0) | 0.11 | 0.53 (0.24-1.18) | 14 (11.6) | **0.01e** | 2.25 (1.16-4.35) |
| 16 | 216 | 4 (0.6) | 0 (0) | 0.18 | 0 (0) | 3 (2.5) | 0.06 | 3.79 (0.83-17.18) |

a*P =* 0.008, OR(95%CI): 1.95 (1.17-3.23): *P*c = 0.08; b*P =* 0.009; OR (95%CI): 7.61 (1.25-46.08): *P*c = 0.09; c*P =* 0.05; OR (95%CI): 0.51 (0.25-1.01): *P*c = 0.5; d*P =* 0.02; OR(95%CI): 2.05 (1.07-3.94): *P*c = 0.2; e*P =* 0.01; OR(95%CI): 2.25 (1.16-4.35): *P*c = 0.1. CD: Crohn disease; UC: ulcerative colitis.

**Table 6 Allele and genotype frequencies of *NOS2A* TAAA polymorphism in inflammatory bowel disease patients and controls *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Controls*n =*295 (%) | IBD patients*n =*190 (%) | CD patients*n =*132 (%) | UC patients*n =*58 (%) |
| Genotype |  |  |  |  |
| 220/220 | 189 (64.07) | 132 (69.47) | 90 (68.18) | 42 (72.41) |
| 220/224 | 97 (32.88) | 49 (25.79) | 34 (25.76) | 15 (25.86) |
| 224/224 | 9 (3.05) | 9 (4.74) | 8 (6.06) | 1 (1.72) |
| Allele | **2*n =*590** | **2*n =* 380** | **2*n =* 264** | **2*n =* 116** |
| 220 | 475 (80.5) | 313 (82.4) | 214 (81) | 99 (85.3) |
| 224 | 115 (19.5) | 67 (17.6) | 50 (19) | 17 (14.7) |

No statistically significant differences were found in any of the comparisons. IBD: inflammatory bowel disease; CD: Crohn disease; UC: ulcerative colitis.